Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib.
about
Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's diseaseNon-steroidal anti-inflammatory drugs as disease-modifying agents for Parkinson's disease: evidence from observational studiesNon-steroidal anti-inflammatory drugs as disease-modifying agents for Parkinson's disease: evidence from observational studiesMyeloid Dendritic Cells are Potential Players in Human Neurodegenerative DiseasesNon-steroidal anti-inflammatory drugs and cognitive function: are prostaglandins at the heart of cognitive impairment in dementia and delirium?The Alzheimer's prevention initiative composite cognitive test score: sample size estimates for the evaluation of preclinical Alzheimer's disease treatments in presenilin 1 E280A mutation carriersApplications of SPR for the characterization of molecules important in the pathogenesis and treatment of neurodegenerative diseasesMicroglial pathologyNeuroinflammation in Alzheimer's disease; A source of heterogeneity and target for personalized therapyFollow-up evaluation of cognitive function in the randomized Alzheimer's Disease Anti-inflammatory Prevention Trial and its Follow-up StudyInflammatory process in Alzheimer's DiseaseDo Microglia Default on Network Maintenance in Alzheimer's Disease?Targeting neuroinflammation in Alzheimer's diseaseAPOE-modulated Aβ-induced neuroinflammation in Alzheimer's disease: current landscape, novel data, and future perspectiveNeuroinflammation in Alzheimer's diseaseCause-specific cardiovascular risk associated with nonsteroidal anti-inflammatory drugs among myocardial infarction patients--a nationwide studyAcetaminophen inhibits neuronal inflammation and protects neurons from oxidative stressAmelioration of amyloid-β-induced deficits by DcR3 in an Alzheimer's disease model.APOE-4 genotype and neurophysiological vulnerability to Alzheimer's and cognitive aging.Microglia change from a reactive to an age-like phenotype with the time in cultureNeuroinflammatory challenges compromise neuronal function in the aging brain: Postoperative cognitive delirium and Alzheimer's disease.Alzheimer's prevention initiative: a proposal to evaluate presymptomatic treatments as quickly as possible.Multitargeted Imidazoles: Potential Therapeutic Leads for Alzheimer's and Other Neurodegenerative Diseases.The Cache County Study on Memory in Aging: factors affecting risk of Alzheimer's disease and its progression after onsetWhy pleiotropic interventions are needed for Alzheimer's disease.An update on the diagnosis and management of dementing conditionsMidlife predictors of Alzheimer's disease.Implications of gliotransmission for the pharmacotherapy of CNS disorders.Is Alzheimer's disease a systemic disease?Using genetics to enable studies on the prevention of Alzheimer's diseaseAlzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments.Interleukin-6 and C-reactive protein as predictors of cognitive decline in late midlife.Estimating and disclosing the risk of developing Alzheimer's disease: challenges, controversies and future directionsProliferation in the Alzheimer hippocampus is due to microglia, not astroglia, and occurs at sites of amyloid deposition.Reelin Signaling, Hippocampal Neurogenesis, and Efficacy of Aspirin Intake & Stem Cell Transplantation in Aging and Alzheimer's disease.Characterizing the preclinical stages of Alzheimer's disease and the prospect of presymptomatic intervention.An empirically derived composite cognitive test score with improved power to track and evaluate treatments for preclinical Alzheimer's disease.Targeting cyclooxygenases-1 and -2 in neuroinflammation: Therapeutic implications.Neuroprotective strategies involving ROS in Alzheimer disease.Neurovascular dysfunction, inflammation and endothelial activation: implications for the pathogenesis of Alzheimer's disease.
P2860
Q24203739-CEDF95D8-1FF6-4E4A-A60A-51647CD5369BQ24235107-2D6AFE57-EA69-403A-9A77-98DD0A89EC50Q24236199-C710D2CA-DDF0-4B35-BD58-D8D4BEDACD5CQ26770676-CAF4708D-D341-4944-965D-38BE5F382F1DQ26822022-8453F12D-4BCD-4853-9050-3FA03040A392Q26849380-C6D74A41-A65E-4219-B0EA-AB9562393957Q26860077-E582F95D-09E3-41E3-A8BD-E6C52EFE6C0AQ26992285-F9CDE165-522C-472C-92C3-BB51185FB067Q27014919-74A7B8A7-C1A3-4611-B8CE-1638015B6E82Q27310286-7613A8CF-86C9-4779-A878-0FA82456DB5FQ27500412-1B7B14F2-0A57-49AC-B408-32F1DE431CF5Q28066112-1F1BD53D-DBA6-47E3-851D-3A310CA9C738Q28078474-251B6538-D08F-44A1-B48A-3826BABA7650Q28085213-3CC7390A-7719-404D-9D28-B4FF6DD337CCQ28259238-A67E8B54-5855-4E52-BF2C-D0EE6CDA462CQ28485380-C7A5938F-8F1E-4FE4-B9D1-88C4A71CD325Q28576204-0DC318A5-C6DD-43D7-98DC-83DE8956C902Q30846817-F634A467-FBB1-482A-9948-DCE435BE9FF2Q33423191-3FCC240D-A3E4-44AD-947C-381AB4FC7232Q33695687-35ACDA7F-A6AA-41DD-96F3-C336D9C67971Q33745149-2833E4AF-3DE8-4866-A92C-0B1238665461Q33773031-08AD9BD1-B0C5-4502-840F-BEBFC9DB7624Q33832795-8DACA55F-9448-4E27-B335-8D417178FDC5Q33873941-8A3F9514-453D-479B-9CAD-88309273D2EBQ33876128-6E39E829-8012-4142-9CE4-22E681137A65Q33896147-4D5EF99A-9BA7-4798-B9F2-5C295A38FB02Q33956934-41009708-C73E-4BBF-B2B7-90D81B926675Q33971765-7DC56448-D56D-40C2-822C-369D85C75720Q34019193-90AF2055-2F6F-428B-B310-866C62AC8545Q34038890-3CC9791D-1B36-4338-90DB-75618984F3DAQ34039983-3F89AD78-0B63-401C-BDE2-8272704FBF8DQ34079309-2F69835C-0907-425F-A791-1E0EC405E234Q34135724-41C0EEC5-B20C-4DC3-B862-35C72A8C1DF1Q34146055-2A9367D3-33C1-49C7-BD6A-81BE388F7F1EQ34193235-6FB6D105-8F70-4FD3-BFED-14BB4044B144Q34303501-5095E417-345C-47F2-AC9F-75BB19AF1CCCQ34364368-EF17C7F5-A80B-492F-821E-5FF10EF81E98Q34432388-6288C89D-739C-41DA-8FEE-84A6F82F841FQ34757939-57662B00-951D-494B-9B3C-0769DE41B86DQ34774194-BFE8E76C-BBFB-4EF6-A3CE-D0E3498098CA
P2860
Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib.
description
2008 nî lūn-bûn
@nan
2008 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
name
Cognitive function over time i ...... ial of naproxen and celecoxib.
@ast
Cognitive function over time i ...... ial of naproxen and celecoxib.
@en
Cognitive function over time i ...... ial of naproxen and celecoxib.
@nl
type
label
Cognitive function over time i ...... ial of naproxen and celecoxib.
@ast
Cognitive function over time i ...... ial of naproxen and celecoxib.
@en
Cognitive function over time i ...... ial of naproxen and celecoxib.
@nl
prefLabel
Cognitive function over time i ...... ial of naproxen and celecoxib.
@ast
Cognitive function over time i ...... ial of naproxen and celecoxib.
@en
Cognitive function over time i ...... ial of naproxen and celecoxib.
@nl
P2093
P2860
P1433
P1476
Cognitive function over time i ...... ial of naproxen and celecoxib.
@en
P2093
ADAPT Research Group
Barbara K Martin
Christine Szekely
Denis Evans
John C S Breitner
Michael Mullan
Robert Green
Suzanne Craft
P2860
P304
P356
10.1001/ARCHNEUR.2008.65.7.NCT70006
P577
2008-05-12T00:00:00Z